Richard Marshall
About Richard Marshall
Richard Marshall, CBE, M.D., Ph.D., is an independent Class III director of Serina Therapeutics, Inc. (SER), age 57, serving since March 2024 with a current term expiring at the 2026 Annual Meeting . He is a physician-scientist with 20 years of leadership in pharmaceutical R&D, formerly SVP and Global Head of Respiratory & Immunology Development at AstraZeneca and earlier senior roles at GlaxoSmithKline; he was recognized with a CBE in 2021 for contributions to UK science and the COVID-19 response and has co-authored 60+ publications in leading journals . He serves on the Nominating & Corporate Governance Committee and is classified as independent under NYSE American rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| AstraZeneca plc | SVP & Global Head, Respiratory & Immunology Development | Sep 2019–Jan 2023 | Oversaw development/approval of five medicines including Vaxzevria (COVID-19 vaccine) and Evusheld (combination antibody) |
| GlaxoSmithKline plc | Increasingly senior R&D roles incl. VP, Fibrosis R&D | 2002–2018 | Led fibrosis programs; broad R&D leadership |
| UK Honours | Commander of the Order of the British Empire (CBE) | 2021 | Recognition for COVID-19 response and UK science |
| Academic/Clinical | Visiting professor (Newcastle University); Honorary consultant (Royal Brompton Hospital) | Various | 60+ publications in The Lancet and NEJM; thoracic medicine expertise |
External Roles
| Organization | Role | Start Date | Notes / Interlocks |
|---|---|---|---|
| Juvenescence Limited | Chief Executive Officer | Jan 2023 | Juvenescence is a >5% SER stockholder (38.2%); Marshall may be deemed to beneficially own shares held by JuvVentures (wholly-owned by Juvenescence) though not admitted beyond his own holdings |
Board Governance
- Board classification: Class III director; term ends 2026 .
- Committee assignments: Nominating & Corporate Governance Committee (member) .
- Independence: Qualifies as independent under NYSE American Section 803(A) .
- Attendance: In 2024, none of SER’s directors attended fewer than 75% of Board and committee meetings on which they served .
- Executive sessions: Non-management directors meet periodically in executive session without management .
- Board leadership: Executive Chairman is Dr. Balkrishan “Simba” Gill; CEO is Steve Ledger (roles separated) .
| Committee | Role | Notes |
|---|---|---|
| Nominating & Corporate Governance | Member | Current members: Karen J. Wilson (Chair), Richard Marshall, Jay Venkatesan |
| Audit | None | Current members: Jay Venkatesan (Chair), Karen J. Wilson |
| Compensation | None | Current members: Karen J. Wilson (Chair), Gregory H. Bailey, Stephen Brannan |
Fixed Compensation
| Component (2024) | Amount (USD) | Notes |
|---|---|---|
| Fees Earned or Paid in Cash | $21,250 | 2024 Director Compensation table |
| Total Cash | $21,250 | 2024 Director Compensation table |
Director Compensation Policy (effective April 1, 2024):
| Role | Annual Retainer (USD) | Notes |
|---|---|---|
| Board member | $40,000 | Paid quarterly, prorated; employees do not receive director fees |
| Audit Chair / Member | $10,000 / $5,000 | Chair receives chair fee only |
| Compensation Chair / Member | $5,000 / $2,500 | Chair receives chair fee only |
| Nominating & Governance Chair / Member | $5,000 / $2,500 | Chair receives chair fee only |
Performance Compensation
| Component (2024) | Grant-Date Fair Value (USD) | Vesting / Metrics |
|---|---|---|
| Option awards | $411,864 | Director awards are time-based (no performance metrics disclosed) |
Director equity program:
- Transition Award: 40,000 stock options for non-employee directors as of policy effective date; vests in equal yearly installments over 3 years, subject to continued service .
- Initial Award: 40,000 options for first-time non-employee directors after effective date; vests in equal yearly installments over 3 years .
- Annual Award: 10,000 options granted at each annual meeting; vests by next annual meeting or one-year anniversary, subject to continued service .
- No performance-based compensation metrics for director equity are disclosed; vesting is service-based .
Other Directorships & Interlocks
| Company | Capacity | Potential Interlock / Conflict Indicator |
|---|---|---|
| Juvenescence Limited | CEO | Juvenescence/JuvVentures holds 38.2% of SER; Marshall may be deemed beneficial owner of JuvVentures-held shares; related-person transactions with Juvenescence are overseen under SER’s Related-Person Transaction Policy |
Expertise & Qualifications
- Physician-scientist with 20 years of pharma R&D leadership; publications in The Lancet and NEJM .
- Led development/approval of five AstraZeneca medicines, including COVID-19 therapeutics (Vaxzevria, Evusheld) .
- Recognized with CBE in 2021 for COVID-19 response and UK science contributions .
- Degrees: B.Sc. Neuroscience, BM/BS (Medicine/Surgery), Ph.D. Medical Sciences (University College London); visiting professor/honorary consultant roles in thoracic medicine .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Outstanding | Composition | |---|---|---| | Richard Marshall | 13,333 | <1% | Options exercisable within 60 days of Sep 17, 2025 |
Notes:
- Marshall, as CEO of Juvenescence (>5% holder), may be deemed to beneficially own shares held by JuvVentures; not admitted beyond securities he actually owns .
Insider Ownership and Section 16 Compliance
| Item | Disclosure |
|---|---|
| Section 16(a) filings | All officers, directors, >10% holders complied for FY2024; exception: Juvenescence Limited filed a late Form 4 on May 18, 2024 (warrants issued April 25, 2023) |
Governance Assessment
- Independence and attendance: Classified independent; no attendance issues (<75%) for 2024; participates in non-management executive sessions—supportive of board effectiveness .
- Committee role: Serves on Nominating & Corporate Governance, relevant to board composition and governance policy oversight .
- Compensation and alignment: 2024 compensation mix shows modest cash ($21,250) and significant equity ($411,864 grant-date fair value) with time-based vesting, aligning director incentives with long-term shareholder value without short-term performance metric risk .
- Potential conflicts/interlocks (RED FLAG potential): CEO of a 38.2% stockholder (Juvenescence); SER executed financing and asset transactions involving Juvenescence/JuvVentures—managed under SER’s Related-Person Transaction Policy with Audit Committee oversight; investors should monitor approvals, disclosures, and terms for arm’s-length treatment .
- Board leadership and risk oversight: Split Chair/CEO structure with Executive Chairman and documented committee risk oversight; Audit/Compensation/N&G committees operate under written charters .
- Trading governance: Insider Trading Policy mandates windows and pre-clearance; Section 16 compliance generally strong (noting Juvenescence’s single late filing) .